SEARCH:   Advanced

Blood, 15 November 2007, Vol. 110, No. 10, pp. 3793-3803. Prepublished online as a Blood First Edition Paper on August 8, 2007; DOI 10.1182/blood-2007-04-086470. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-04-086470v1 110/10/3793    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Fujita, S. Articles by Sato, K. Search for Related Content PubMed PubMed Citation Articles by Fujita, S. Articles by Sato, K. Related Collections Transplantation Immunobiology Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  TRANSPLANTATION Regulatory dendritic cells protect against cutaneous chronic graft-versus-host disease mediated through CD4+CD25+Foxp3+ regulatory T cells Shigeharu Fujita1,2, Yumiko Sato1, Kaori Sato1, Kawori Eizumi1, Tomohiro Fukaya1, Masato Kubo3, Naohide Yamashita2, and Katsuaki Sato1 Laboratories for 1 Dendritic Cell Immunobiology, Rikagaku Kenkyusho (RIKEN) Research Center for Allergy and Immunology, Yokohama; 2 Department of Advanced Medical Science, The Institute of Medical Science, The University of Tokyo, Tokyo, and 3 Laboratory for Signal Network, RIKEN Research Center for Allergy and Immunology, Yokohama, Japan Chronic graft-versus-host disease (cGVHD) is a common cause of morbidity and mortality in allogeneic bone marrow transplantation (alloBMT). However, effective strategies for the treatment of cGVHD have not been established. In this study, we examined the therapeutic utility of modified dendritic cells (DCs) with a greater capacity to regulate immune responses than previously known tolerogenic DCs, regulatory DCs (DCregs), in the major histocompatibility complex-compatible, and multiple minor histocompatibility antigen-incompatible model of cGVHD in alloBMT. Treatment of the recipient mice after alloBMT with the recipient-type DCregs led to greater suppression of the incidence and severity of cutaneous cGVHD than rapamycin, whereas treatment with the recipient-type mature DCs promoted the pathogenesis. Analysis of the recipient mice suggested that the protective effect of the recipient-type DCregs involved the peripheral generation of alloreactive CD4+CD25+Foxp3+regulatory T (TR) cells from donor-derived CD4+CD25–Foxp3– T cells. Thus, immunotherapy with DCregs is a promising strategy for the treatment of cGVHD in alloBMT mediated through the induction of a dominant tolerance involving CD4+CD25+Foxp3+ TR cells. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: Regulatory T cells and the pursuit of self-tolerance Allan D. Hess Blood 2007 110: 3497-3498. [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020